Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Ingevity's (NGVT) Earnings Beat Estimates In Q2, Sales Lag

Published 07/25/2019, 08:25 AM
Updated 07/09/2023, 06:31 AM

Ingevity Corporation (NYSE:NGVT) logged profits (attributable to stockholders) of $56.8 million or $1.34 per share in second-quarter 2019, up from $46.7 million or $1.10 a year ago.

Adjusted earnings per share for the quarter were $1.36, up from $1.11 a year ago. The results surpassed the Zacks Consensus Estimate of $1.35.

The company’s revenues rose roughly 14% year over year to $352.8 million in the quarter, but fell short of the Zacks Consensus Estimate of $365.7 million.

Adjusted EBITDA climbed roughly 21% year over year to $108.3 million in the quarter. While the chemical maker faced challenges from weaker industrial demand in the quarter, it gained from its inorganic and organic growth strategy and focus on driving margins and profitability.

Ingevity Corporation Price, Consensus and EPS Surprise

Ingevity Corporation price-consensus-eps-surprise-chart | Ingevity Corporation Quote

Segment Review

Revenues from the Performance Chemicals division rose around 8% year over year to $229.7 million in the quarter. Revenues were driven by the addition of the engineered polymers product line through the acquisition of the Capa caprolactone business.

Revenues from the Performance Materials unit went up around 28% to $123.1 million, driven by strong sales to automotive customers in China. The growth was also supported by strong growth in sales of the company’s solutions geared to meet the U.S. EPA Tier 3 and California LEV III automotive emission regulations.

Balance Sheet

Ingevity ended the quarter with cash and cash equivalents of $53.3 million, down around 36% year over year. Long-term debt was $1,363.3 million, up around 87%.

Outlook

Ingevity reaffirmed its sales guidance of between $1.30 billion and $1.36 billion for 2019. It also backed its adjusted EBITDA guidance for the year in the band of $390-$410 million.

Price Performance

Shares of Ingevity have rallied 24.6% year to date, outperforming the industry’s 20.8% rise.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .



Zacks Rank & Key Picks

Ingevity currently carries a Zacks Rank #4 (Sell).

Better-ranked stocks worth considering in the basic materials space include Israel Chemicals Ltd. (NYSE:ICL) , Flexible Solutions International Inc (NYSE:FSI) and Air Products and Chemicals, Inc. (NYSE:APD) .

Israel Chemicals has an expected earnings growth rate of 13.5% for the current year and carries a Zacks Rank #1 (Strong Buy). Its shares are up roughly 8% in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here.

Flexible Solutions has an expected earnings growth rate of 342.9% for the current fiscal year and carries a Zacks Rank #2 (Buy). Its shares have surged around 151% in the past year.

Air Products has an expected earnings growth rate of 10.3% for the current fiscal year and carries a Zacks Rank #2. The company’s shares have gained around 39% over the past year.

This Could Be the Fastest Way to Grow Wealth in 2019

Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.

These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.

Click here to see these breakthrough stocks now >>



Air Products and Chemicals, Inc. (APD): Free Stock Analysis Report

Israel Chemicals Shs (ICL): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Flexible Solutions International Inc. (FSI): Free Stock Analysis Report

Ingevity Corporation (NGVT): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.